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Aims: Conflicting evidence exists regarding the potential risk of pancreatic cancer with use of incretin drugs in 2 
patients with type 2 diabetes (T2DM). We performed a meta-analysis of randomised controlled trials (RCTs), 3 
including six recently published large-scale cardiovascular outcome trials (CVOTs), to evaluate the risk of 4 
pancreatic cancer with incretin-based therapies in patients with T2DM. 5 
Materials and methods: The PubMed, Embase, Cochrane Central Register and ClininalTrials.gov databases were 6 
searched for RCTs in T2DM that compared incretin drugs with placebo or other antidiabetic drugs, with treatment 7 
and follow-up durations of no less than 52 weeks, from January 1, 2007 to May 1, 2017. Two reviewers screened 8 
the studies, extracted the data and assessed the risk of bias independently and in duplicate.  9 
Results: Thirty-three studies (n=79,971), including the six CVOTs, with 87 pancreatic cancer events were 10 
identified. Overall, the pancreatic cancer risk was not increased in patients administered with incretin drugs 11 
compared to controls (Peto OR 0.67 [95%CI 0.44 to 1.02]). In the six CVOTs, 79 pancreatic cancer events were 12 
identified in 55,248 subjects. Pooled estimates of the six CVOTs displayed the identical tendency (Peto OR 0.65 13 
[95%CI 0.42 to 1.01]). Notably, in the subgroup of patients who received treatment and follow-up for 104 weeks 14 
or more, 84 pancreatic cancer events were identified in 59,919 subjects, and a lower risk of pancreatic cancer was 15 
associated with incretin-based therapies (Peto OR 0.62 [95%CI 0.41 to 0.95]). 16 
Conclusions: Treatment with incretin drugs is not associated with an increased risk of pancreatic cancer in patients 17 
with T2DM. Instead, it might protect against the pancreatic malignancy in patients treated for 104 weeks or more. 18 
The major limitations of this study are that pancreatic safety was not the primary outcome of these enrolled trials, 19 
and the event number and follow-up time are limited. 20 





Incretin-based therapies include glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-23 
4 (DPP-4) inhibitors. They demonstrate an anti-hyperglycaemic effect in a glucose-dependent manner and are 24 
beneficial for weight control. Recently, encouraging results from two cardiovascular outcome trials (CVOTs) have 25 
shown that GLP-1 receptor agonist can reduce the risk of major adverse cardiovascular events in patients with type 26 
2 diabetes (T2DM) who are at high cardiovascular risk.1,2 Because of these favourable features, incretin drugs have 27 
been recommended as important therapeutic options for patients with T2DM.3 28 
However, concerns have been raised for years about the pancreatic safety of incretin drugs. In 2011, Elashoff 29 
and colleagues4 reported that increased risks of both pancreatitis and pancreatic cancer were associated with the 30 
use of incretin drugs. Thereafter, attempts have been made to investigate the safety of incretin-based therapies. 31 
However, results from the preclinical reports5-7 and observational cohort studies8-11 are conflicting. Notably, the 32 
incidence of pancreatic cancer is low12. No individual trial has enough power to assess the risk of pancreatic 33 
malignancy sufficiently. Therefore, pooling data from large randomised controlled trials (RCTs) would be an 34 
alternative method of investigating this safety issue. 35 
Recently, CVOTs of incretin drugs (e.g. EXAMINE,13 SAVOR,14 TECOS,15 ELIXA,16 LEADER1 and 36 
SUSTAIN-62) have been completed or are ongoing. In these trials, a large number of patients were followed up 37 
for relatively longer periods and managed with a similar glycated haemoglobin (HbA1c) achievement goal. 38 
Accordingly, pooling data from these CVOTs might help researchers better understand the true risk of pancreatic 39 
malignancy with incretin-based therapies. 40 
Here, we performed a meta-analysis of large RCTs, including the six recently published CVOTs, to evaluate 41 





2∣MATERIALS AND METHODS 44 
2.1∣Data sources and searches 45 
The PubMed, Embase and Cochrane Central Register databases were searched from January 1, 2007 to May 46 
1, 2017 for RCTs that involved incretin drugs and were published in English. Medical subject headings and free 47 
text terms were used to identify the related articles. An endocrinologist, together with an epidemiologist, developed 48 
the search strategy (S1 Text, Supporting information). The ClinicalTrials.gov was searched using the same method 49 
to identify trials that were complete but unpublished. It also provided us with extended information about adverse 50 
events related with the selected trials. The search was performed on May 1, 2017. 51 
 52 
2.2∣Study selection 53 
We selected trials that satisfied the following criteria: 1) study type, RCTs; 2) subjects, adult patients with 54 
T2DM; 3) intervention and comparators, trials that compared the effects of incretin drugs (GLP-1 receptor agonists 55 
or DPP-4 inhibitors) with comparators (placebo or other antidiabetic drugs); 4) duration of treatment and follow-56 
up, it is estimated that the mean time from first malignant cell to the clinical diagnosis of pancreatic cancer is 0.7 57 
years in males and 0.6 years in females,17 therefore, we only included trials that had a treatment and follow-up 58 
time at least 52 weeks to reduce the bias related to the undiscovered pancreatic cancer before start of intervention; 59 
5) sample size restriction, pancreatic cancer has a low incidence (10-14 per 100,000 person years),12 to reduce 60 
sampling variation, we only included the trials with at least 500 randomised subjects; and 6) outcome evaluation, 61 
the trials were required to have clear information of pancreatic malignancy, or at least systemic reports of 62 
neoplasms in the supplemental materials or in the data posted on ClinicalTrials.gov. 63 
 64 




Data were collected from published papers or from ClinicalTrials.gov documents (for unpublished trials). 66 
Two trained reviewers screened the literature for eligible studies. A pilot format was used for the reviewers to 67 
evaluate the risk of bias and to collect data independently and in duplicate for each included trial. Disputes were 68 
discussed by the study group and were adjudicated by the study supervisor. For multiple reports of one trial, we 69 
only documented the data from the report with the longest follow-up. For each eligible trial included in this study, 70 
the characteristics of the trials, including National Clinical Trial (NCT) codes (if available), sample size, the 71 
number of participants in each treatment group, duration of treatment and follow-up, percentage of male 72 
participants, age and body mass index (BMI) of the participants, duration of diabetes and baseline HbA1c level 73 
were recorded. As glycaemic control status may affect the risk of cancer,18 we also recorded the final HbA1c 74 
difference between the groups. An HbA1c difference of more than 0.4% was regarded as clinically significant.19 75 
The pancreatic cancer events in each group were recorded separately. The number of patients exposed to each 76 
treatment group was recorded using intention-to-treat (ITT) data. 77 
A modified Cochrane Collaboration’s tool, which includes information about the randomisation process, 78 
allocation concealment, blindness, adjudication of outcomes and selective reporting, was used to assess the risk of 79 
bias in each trial.20 We used funnel plot asymmetry to detect whether there was publication bias and Egger’s 80 
regression test to measure funnel plot asymmetry in Stata 11.0.21 81 
 82 
2.4∣Data synthesis and analysis 83 
We assessed heterogeneity between studies using both Chi2 and I2 statistics. Pancreatic cancer is rare, and the 84 
Peto method is recommended and has a relatively good reputation for rare events,20 therefore, pooled risk was 85 
reported with the Peto odds ratio (OR) and 95% confidence interval (CI); p<0.05 was considered to be significant. 86 




of events.20 To determine the possible factors that might affect the risk of pancreatic cancer, we performed four 88 
prespecified subgroup analyses, according to the following stratifications: the duration of treatment and follow-up 89 
(52 to 103 weeks or no less than 104 weeks), class of incretin drugs (GLP-1 receptor agonists or DPP-4 inhibitors), 90 
type of comparators (placebo or other non-incretin antidiabetic drugs), and level of HbA1c difference between 91 
treatment arms at the end of trials (more than 0.4% or not). In addition, a sensitivity analysis was performed using 92 
alternative effect measures (OR vs. relative risk), pooling methods (Peto method vs. Mantel-Haenszel method), 93 
and consideration of heterogeneity (fixed effect vs. random effect). We reported our results, according to the 94 
PRISMA statement.22 95 
 96 
3∣RESULTS 97 
Among the 5,416 potential reports from PubMed, Embase and Cochrane Central Register, and 305 reports 98 
from ClinicalTrial.gov, we identified 622 reports for full-text reviews. Finally, thirty-three RCTs,1,2,13-16,23-49 99 
including the six recently reported CVOTs,1,2,13-16 fulfilled the inclusion criteria (32 from published journals and 1 100 
unpublished trial from ClinicalTrials.gov). A flow diagram of the trial selection is presented in Figure 1. For all 101 
included studies, the average age of the participants ranged from 51.8 to 72.6 years, and the mean BMI ranged 102 
from 24.9 to 37.1 kg/m2, with a mean duration of diabetes ranging from 1.0 to 13.9 years. The percentage of male 103 
subjects ranged from 43% to 71%. The average baseline HbA1c level ranged from 7.2% to 9.2%. The mean or 104 
median follow-up time ranged from 52 to 198 weeks (Table 1). 105 
3.1∣Quality of the included trials and publication bias 106 
Among the included trials in our analysis, randomisation was well designed in 31 studies. One trial did not 107 
mention how the random sequence was generated. One trial was at high risk of bias because its randomisation was 108 




without treatment concealment to the investigators and participants were regarded as having a high risk of bias. 110 
As for the outcome evaluation, all included studies provided safety data for the ITT population, and the six CVOTs 111 
and nine non-CVOT studies had an independent adjudication committee for the cancer and pancreatitis events, 112 
which were at low risk of bias (Table S1, Supporting information). 113 
The funnel plot was symmetric (Egger’s test P=0.887) (Figure S1, Supporting information). Moreover, all 114 
included trials were designed to test the drug’s efficacy of glucose lowering or the safety of cardiovascular 115 
outcomes. Therefore, pancreatic cancer and pancreatitis events had a minor effect on the selected publications. 116 
 117 
3.2∣Risk of pancreatic cancer in the pooled analysis 118 
Of the 33 included RCTs, eleven studies reported pancreatic cancer events. Thirty-five events were reported 119 
in 42,233 incretin group subjects, and 52 events were reported in 37,738 control group subjects. Pooled estimates 120 
of the 33 trials (n=79,971) showed that no increased risk of pancreatic cancer was associated with the incretin 121 
drugs compared to the controls (Peto OR 0.67 [95%CI 0.44 to 1.02]). In particular, in the six CVOTs, thirty-three 122 
events were reported in 27,663 subjects in the incretin group, and 48 events were reported in 27,585 control group 123 
subjects. The Peto OR of the pooled analysis of the six CVOTs (n=55,248) was 0.65 [95%CI 0.42 to 1.01] (Figure 124 
2). 125 
 126 
3.3∣Risk of pancreatic cancer in the subgroup analysis 127 
When evaluating the effect of incretin drugs on the risk of pancreatic cancer, the exposure time is an important 128 
factor. Among the trials that followed subjects for 52-103 weeks, three pancreatic cancer events in 11,765 incretin 129 
users and no events in 8,287 non-incretin users were observed (Peto OR 5.63 [95%CI 0.52 to 60.4]) (Figure S2, 130 




more, the risk of pancreatic cancer decreased significantly, compared to subjects who received the control 132 
treatment (Peto OR 0.62 [95%CI 0.41 to 0.95]) (Figure 3). 133 
 No significant difference in the risk of pancreatic cancer was observed in the subgroup analysis of the class 134 
of incretin drugs (Peto OR 0.77 [95%CI 0.42 to 1.42] for GLP-1 receptor agonists and 0.59 [95%CI 0.33 to 1.05] 135 
for DPP4 inhibitors). In the subgroup analysis of the type of comparators, we did not find any significant difference 136 
in the risk of pancreatic cancer in the subgroups of incretins vs. active controls (Peto OR 1.12 [95%CI 0.25 to 137 
5.06]), such as metformin, thiazolidinediones, sulfonylureas, insulin and sodium-dependent glucose transporters 2 138 
inhibitors. A decreased risk of pancreatic cancer was observed in the incretin group compared to the placebo group 139 
(Peto OR 0.63 [95%CI 0.40 to 0.97]). In addition, there was no significant difference in the risk of pancreatic 140 
cancer between the incretin-based and control therapies in the subgroup stratified by the level of the final HbA1c 141 
difference (Peto OR 0.70 [95%CI 0.45 to 1.09] and 0.45 [95%CI 0.12 to 1.70] for the subgroups with HbA1c 142 
differences ≤0.4% and >0.4%, respectively) (FigureS3-5, Supporting information). 143 
 144 
3.4 ∣Risk of pancreatitis in the pooled analysis 145 
The overall pancreatitis risk was not increased in the incretin group compared with the control group (Peto 146 
OR 1.12 [95%CI 0.85 to 1.47]). Pooled analysis of the six CVOTs did not show an increased risk of pancreatitis 147 
associated with incretin-based therapies (Peto OR 1.06 [95%CI 0.80 to 1.42]) (Figure S6, Supporting information). 148 
 149 
3.5∣Sensitivity analysis 150 
The sensitivity analysis of pancreatic cancer risk using an alternative pooling method (Mantel-Haenszel OR 151 








Overall, we screened 5,721 studies and included 33 eligible RCTs reporting 87 pancreatic cancer events 157 
among 79,971 patients. We found that compared with the controls, treatment with incretin drugs was not associated 158 
with an increased risk of pancreatic cancer in patients with T2DM. Instead, use of incretin drugs for 104 weeks or 159 
more might even decrease the risk of pancreatic malignancy by 38% compared with controls. 160 
The association between incretin-based therapies and pancreatic cancer has drawn a great concern recently. 161 
Unfortunately, neither preclinical studies 5-7,50 nor the following cohort studies have answered this question 162 
consistently. 8-11,51,52 In a recent large multinational cohort study, the risk of pancreatic cancer even seemed to be 163 
lower with longer incretin-based therapy durations (HR 1.53 [95%CI 0.93 to 2.51], 1.07 [95%CI 0.82 to 1.39] and 164 
0.62 [95%CI 0.36 to 1.07] for duration of use <1 year, 1-1.9 years and 2 years, respectively), although the 165 
difference was not statistically significant.8 Additionally, the United Kingdom clinical practice research datalink 166 
(UK-CPRD) cohort study has reported that the minor increase of pancreatic cancer risk in new incretin users 167 
[adjusted HR 1.67 (1.01–2.77)] was likely caused by protopathic bias because of the lack of a duration of use and 168 
dosage effect for incretin agents on pancreatic cancer risk.11 Inconsistency and methodological limitations 169 
undermined the strength of those results. In the cohort studies, baseline characteristics and metabolic control levels 170 
could not be well matched between groups. Even in the nested case-control study, the incretin group still differed 171 
from the control group in the parameters that could affect the incidence of malignancy, including age, duration of 172 
diabetes, BMI and HbA1c levels.8 Furthermore, in most cohort studies, the report of pancreatic cancer events was 173 




Nevertheless, cohort studies are from the real world. It is rational to take the results from cohort studies and 175 
meta-analyses of RCTs together into consideration when evaluating the risk of pancreatic malignancy. Recently, 176 
two meta-analyses by Monami and colleagues have suggested that there is no increased risk of pancreatic cancer 177 
associated with the use of incretins.53,54 In the 2014 report, the primary outcome was pancreatitis, and the data 178 
collection was not based on pancreatic cancer.53 In addition, the sample size of each trial varied greatly (from 24 179 
to 9340). The follow-up durations of the enrolled trials were not long enough (more than 70% of the trials had 180 
follow-up durations of 12-51 weeks), 53,54 which did not take the latent period of cancer into consideration.  181 
 In our study, we enrolled qualified RCTs with baseline characteristics that were balanced between the groups. 182 
The drug exposure and follow-up were clear and well managed. All patients treated with incretin drugs were new 183 
users, thereby avoiding the bias in cohort studies caused by combining new users with prevalent users and the 184 
possible protopathic bias11. Note that pancreatic cancer is insidious and rare. The estimated time from first 185 
malignant cell to the clinical diagnosis of pancreatic cancer is 0.6-0.7 year.17 Therefore, we only included trials 186 
with treatment and follow-up durations of at least 52 weeks to reduce the possibility of occult pancreatic 187 
malignancy at the start of trials, and we excluded studies with fewer than 500 subjects in case that cancer events 188 
reported in small trials by chance could dramatically affect the incidence. Recently, several large-scale CVOTs of 189 
incretin drugs have been completed or are ongoing. A large number of patients (from 3,927 to 16,492) were 190 
enrolled, and the duration of follow-up was much longer (median duration ranged from 1.5 to 3 years) in these 191 
trials. Moreover, the primary endpoint of these CVOTs was drug safety rather than efficacy, and patients in 192 
different intervention groups were managed under a similar glycaemic goal. Therefore, the differences in the 193 
HbA1c level achieved between the incretin and control groups were relatively small, providing a more parallel 194 
metabolic status. Accordingly, pooling data from these CVOTs might help us to better understand the pancreatic 195 




could provide us with valuable information about pancreatic safeness, and they provided good evidence against 197 
previous estimates of the increased pancreatic cancer risk.57 We collected all available RCTs with follow-up times 198 
of at least 52 weeks, thus, our results could further support their conclusion. 199 
It is known that patients with T2DM are at high risk of developing pancreatic cancer, with high mortality 200 
rates.58 Unfortunately, pancreatic cancer still lacks an effective management strategy and even presents with 201 
increasing incidence and mortality.12 Here, our subgroup analysis showed that treatment with incretin drugs for 2 202 
years or more significantly reduced the risk of pancreatic cancer, compared to the controls, by 38%. Notably, a 203 
similar trend was also observed in the large nested case-control cohort study mentioned above (HR 0.62 [95%CI 204 
0.36 to 1.07]).8 Signals from laboratory studies have also suggested an anti-tumour effect of incretin drugs. In our 205 
previous studies, we found that GLP-1 receptor levels were lower in cancer tissues than in tumour adjacent 206 
pancreatic tissues, and a lower GLP-1 receptor level was associated with poorer prognoses in patients with 207 
pancreatic cancer. Moreover, GLP-1 receptor activation with liraglutide inhibited growth and promoted apoptosis 208 
of human pancreatic cancer cells in a GLP-1 receptor-dependent manner in vitro, and attenuated pancreatic tumour 209 
growth in a mouse xenograft model in vivo.59, 60 In agreement with our previous findings, it has been shown that 210 
GLP-1 receptor agonist exendin-4 can inhibit cell growth in colon cancer cells61 and breast cancer cells62, 63 in vitro 211 
and in vivo. Furthermore, exendin-4 also counteracts the invasive potential of human neuroblastoma cells.64 These 212 
consistent signals from clinical and laboratory studies suggest that long-term incretin-based therapies might shed 213 
some light on how to prevent the development and progression of pancreatic malignancy, which usually has a poor 214 
outcome. 215 
GLP-1 receptor agonists and DPP-4 inhibitors are both incretin drugs, however, they act differently. GLP-1 216 
receptor agonists directly and intensively stimulate GLP-1 receptor and its downstream signalling pathways, while 217 




degradation. Hence, it has been suggested to analyse them separately.56 Here, we found no difference between 219 
GLP-1 receptor agonists and DPP-4 inhibitors, in terms of their association with pancreatic cancer risk. It is well 220 
known that diabetes itself is an independent risk factor for pancreatic cancer and its high mortality.12,58 Although 221 
patients had parallel baseline HbA1c levels when they entered a trial, they received different antidiabetic therapies 222 
and might significantly vary in their glycaemic control. Therefore, we conducted a prespecified subgroup analysis 223 
based on a 0.4% difference in the final HbA1c level, which is usually considered to be the non-inferiority margin,19 224 
to clarify whether our result would be altered by glycaemic control variations. Again, we could not find any 225 
increased risk of pancreatic cancer associated with incretin drugs in the subgroups stratified by level of HbA1c 226 
difference, suggesting the consistency of the observations that incretin drugs were not the promoter of pancreatic 227 
cancer. 228 
It has been argued that incretin drugs were a potential inducer of acute and chronic pancreatitis, 65-67 thus in 229 
the long run promoting the development of pre-neoplastic lesions and increasing the risk of pancreatic cancer. 230 
However, increasing reports from clinical trials,68 cohort studies69,70 and systemic reviews53,71 have shown no 231 
increased risk of pancreatitis associated with incretin-based therapies. Here, we also found results similar to those 232 
reports, providing additional evidence for the pancreatic safety of incretin-based therapies. 233 
Several limitations should be considered in our study. First, pancreatic safety was not the primary outcome 234 
of the included trials, and the number of pancreatic cancer events in our study was relatively smaller than that in 235 
some observational cohort studies.8, 9,11 This limitation is primarily attributed to the nature of RCTs because it is 236 
not practical for a RCT to enrol such a large population as the cohort studies performed using databases. 237 
Nevertheless, signals from our study and most cohort studies consistently suggest that incretin drugs were not the 238 
carcinogen of pancreatic malignancy. Second, we noticed that 91% of pancreatic cancer events were reported in 239 




of 95%CI in the non-CVOT studies. There might be underreporting in some of the non-CVOTs with no pancreatic 241 
malignancies reported. However, the nature of RCTs could partially balance the possibility of underreporting. 242 
Moreover, the total number of pancreatic cancer events in our pooling data was 87 in 79,971 subjects 243 
(approximately 108 per 100,000 persons). The estimated overall incidence was approximately 47 per 100,000 244 
person years in all trials and 55 per 100,000 person years in trials with follow-ups of 104 weeks or more, which 245 
was much higher than that in the general population (10-14 per 100,000 person years)12 and similar to that reported 246 
in a previous large cohort study in patients with T2DM (60 per 100,000 person years).8 Therefore, there might be 247 
no obvious underreporting in the trials included in our study, and the limited number of the cancer events may not 248 
substantially undermine our results. Third, we did not have the primary time-to-event data for all included trials, 249 
and it is possible that a risk of immortal time bias might exist in our subgroup analysis. However, in the nested 250 
case-control cohort study, the declined tendency of pancreatic cancer risk was also found among the subjects 251 
treated with incretin drugs for 2 years or more.8 Furthermore, incretins are not carcinogens, and they may influence 252 
the rate of neoplasm progression and affect the time period from the first malignant cell to the clinical diagnosis 253 
of pancreatic cancer. Theoretically, the longer the exposure, the more significant effect could be found. Therefore, 254 
pooling data from more large-scale trials with long-term incretin-based therapies, particularly the CVOTs with the 255 
primary time-to-event data, might provide us with a clearer picture on this topic. Fourth, we did not identify 256 
pancreatitis as acute or chronic, partly because some trials did not define or report pancreatitis in detail. After all, 257 
it was not the primary outcome in this analysis. 258 
 259 
In conclusion, our meta-analysis of 33 RCTs involving 79,971 subjects suggests that treatment with incretin 260 
drugs for no less than 52 weeks is not associated with an increased risk of pancreatic cancer in patients with T2DM. 261 




patients with T2DM who received the treatment for 104 weeks or more. Even so, it is difficult to verify this issue 263 
in a single study because pancreatic cancer is rare and occult. Accordingly, pooling more data from large-scale 264 
RCTs, particularly long-term CVOTs, may help us to find the true answer to the question of whether incretin-265 
based therapies are safe and might even protect patients with T2DM against pancreatic malignancy. 266 
 267 
Figure and table legends. 268 
Figure 1. Flow diagram of trial selection 269 
 270 
Table 1. Characteristics of randomised controlled trials of incretin-based therapies and pancreatic cancer 271 
events in patients with type 2 diabetes 272 
NCT, National Clinical Trial. NR, not reported. * Final HbA1c (%) difference: incretin group vs. control group at 273 
the end of the trial. † There was no publication of the studies, and presented here is the time of the last data update 274 
on ClinicalTrial.gov website. § Sitagliptin/metformin fixed-dose combination. ‡ No report of pancreatic cancer in 275 
the article, but there were systemic reports of neoplasms in the supplemental materials or in the data posted on the 276 
ClinicalTrial.gov website. 277 
 278 
 279 
Figure 2. Risk of pancreatic cancer in patients with type 2 diabetes who were treated with incretin drugs or 280 
controls. 281 
CVOT, cardiovascular outcome trial. 282 
 283 
Figure 3. Risk of pancreatic cancer in patients with type 2 diabetes who were treated with incretin drugs or 284 
controls and followed up for 104 weeks or more. 285 
 286 
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